Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Antibodies Ltd. - Common Stock (NQ:IPA)

2.070 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ImmunoPrecise Antibodies Ltd. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Biotech Recovery Accelerates These Companies Benefit (IPA, SIGA, MNKD, INO, CTIC)
Via AB Newswire
News headline image
IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense
From Elektrofi and ImmunoPrecise Antibodies
Via Business Wire
News headline image
Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant – Moves Towards FDA/IND-Submission
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies Announces Grant of Stock Options
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies Announces Grant of Stock Options
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies Announces Grant of Stock Options
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration
From IMMUNOPRECISE ANTIBODIES LTD.
Via Business Wire
News headline image
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise to Present at the Benchmark Company’s Discovery One-on-One Virtual Video Investor Conference on Thursday December 2, 2021
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Announces Resignation of Director
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre
From ImmunoPrecise Antibodies Ltd
Via Business Wire
News headline image
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Announces Participation at the H.C. Wainwright 23nd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Accelerating Its Growth and Expansion Plans
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform
From ImmunoPrecise Antibodies
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.